CD8A and cancer: It has been reported that TP53 mutations are related to increased leukocyte infiltration across 30 diverse cancer types, and higher TMB and higher proportions of PD-L1–expressing CD8+ T cells correlate with beneficial responses to pembrolizumab immunotherapy in patients with TP53-mutated lung adenocarcinoma (20, 21).